vaccines are now at the center of a sudden leadership jolt inside the US advisory system after Robert Malone stepped away from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP). The move, confirmed Tuesday, follows a federal court ruling that effectively nullified the panel and blocked its recent changes to the childhood vaccine schedule. The disruption is immediate, with the CDC vaccine advisory barred from convening until a decision is reached in the court case, all as of Tuesday morning (ET).
What happened: Malone exits after feud and court decision
Robert Malone, a physician and biochemist described as an ideological ally of Health and Human Services Secretary Robert F. Kennedy Jr., said Tuesday he will not take part in any attempt to reform ACIP after an internal dispute over whether the government would appeal the court ruling.
In a text message sent Tuesday morning (ET), Malone said: “After Andrew trashing me with the press, I am done with the CDC and ACIP. That was the last straw. ” He added: “Suffice to say I do not like drama, and have better things to do. ”
The rupture comes after a federal judge last week blocked ACIP’s controversial changes to the childhood vaccine schedule and questioned the panel’s validity, leaving it effectively unable to take future actions. The court action also stayed the appointment of 13 ACIP members, invalidating their roles and the decisions they have made.
Immediate reactions from HHS and ACIP leadership
Andrew Nixon, spokesperson for the US Department of Health and Human Services (HHS), contradicted Malone’s public post suggesting the court decision would not be appealed. Nixon also rejected assertions about what the department would do next without an official announcement, calling such claims “baseless speculation”.
Martin Kulldorff, former ACIP chair and now Chief Science Officer for the Office of the Assistant Secretary for Planning and Evaluation at HHS, acknowledged Malone’s departure read after contact from Rich Danker, HHS Assistant Secretary of Public Affairs. Kulldorff said: “In light of the court ruling and the enormous amount of volunteer time provided by ACIP members to enhance public health, I can sympathize with his decision to step away. As for Andrew Nixon, I found him to be professional and honest in all his work supporting ACIP. ”
In his time on the panel, Malone supported more limited COVID-19 vaccine recommendations, arguing Americans should be guided by consultations with health care providers rather than “propaganda, marketing and other activities that are not based in an actual, real world assessment of their risks and benefits. ”.
What the ruling means for recommendations and access
The court ruling halted ACIP’s recent changes to the childhood vaccine schedule, changes made after Kennedy fired all 17 committee members last summer and replaced them with handpicked allies, many described as vaccine skeptics. In recent months, the committee removed recommendations including the birth-dose hepatitis B vaccine, rotavirus vaccine, and the annual flu shot, among others.
Separately, the disruption leaves several key shots in limbo, including the latest version of flu and Covid shots and the inclusion of the RSV shot for infants in the federal Vaccines for Children program, which covers immunizations for more than half of US children.
The CDC vaccine advisory typically develops recommendations on the use of vaccines after Food and Drug Administration approval, including guidance tied to new flu shots and COVID-19 boosters. Even without ACIP input, new vaccines can still go into circulation.
Quick context on the broader shakeup
The upheaval inside ACIP has been building since last summer’s wholesale firing and replacement of the committee, followed by high-profile disputes over the direction of the childhood schedule. The court ruling has now frozen the panel’s ability to meet, amplifying uncertainty over near-term federal guidance.
What’s next: court timeline, leadership decisions, and the road ahead
With vaccines policy guidance tied to an advisory system that cannot currently convene, the next developments hinge on the court case and any formal HHS decisions about an appeal or a reconstituted committee. Separately, Donald Trump is expected to name a new CDC director on Wednesday (ET); he must name a new head within 210 days of the prior director’s departure or acting directors are no longer able to carry out their work. Until the legal status of ACIP is resolved, the government faces a narrowed path for issuing updated recommendations, even as products may still enter circulation after FDA approval.